KURN Kuros Biosciences AG

22.29USD18.78 CHF · SWX-3.10%Mkt Cap: 886.09M USDP/E: 110.47

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two se…

Institutional holders10 on file

Key Statistics

Company
Market Cap886.09M USD
Enterprise Value892.92M USD
Revenue (TTM)174.93M USD
Gross Profit129.40M USD
Net Income (TTM)2.55M USD
Revenue/Share4.56 USD
Last Price22.29 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees213
CountryCH
SectorHealthcare
IndustryMedical Devices
ISINCH0325814116
Valuation
P/E (Trailing)110.47
P/E (Forward)34.04
PEG—
EV/EBITDA57.50
EV/Revenue5.10
P/S4.27
P/B10.22
EPS (TTM)0.17 USD
EPS (Forward)0.55 USD
52W Range
19.5314% of range38.55
52W High38.55 USD
52W Low19.53 USD
Profitability
Gross Margin88.60%
Oper. Margin6.07%
EBITDA Margin7.48%
Profit Margin1.75%
ROE3.02%
ROA1.91%
ROIC6.69%
ROCE9.75%
Growth
Revenue Growth45.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-455.00K USD
CapEx (TTM)2.44M USD
FCF Margin-5.35%
FCF Yield-1.06%
Net Debt334.00K USD
Net Debt/EBITDA0.03
Net Debt/FCF—
Balance Sheet
Debt/Equity0.02
Current Ratio1.87
Quick Ratio1.22
Book Value/Sh1.84 USD
Cash/Share0.24 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateOct 8, 2020
Splits
Last Split1:100
Split DateJun 23, 2016
Analyst Consensus
Rating—
Target (Mean)40.75 USD
Upside (mean)+82.8%
Target Range37.98 USD – 45.10 USD
37.98+82.8% to mean45.10
# Analysts3
Ownership
Shares Out.39.76M
Float30.59M
Insiders33.80%
Institutions23.55%
Technical
SMA 5022.33 (-0.2%)
SMA 20025.22 (-11.6%)
Beta0.72
S&P 52W Chg8.68%
Avg Vol (30d)209.60K
Avg Vol (10d)134.01K
Technical Indicators
RSI (14)44.1
MACD-0.0078
MACD Signal0.1798
MACD Hist.-0.1876
BB Upper25.27 USD
BB Middle23.74 USD
BB Lower22.21 USD
BB Width12.88%
ATR (14)1.044 USD
Vol Ratio (20d)0.85x

About Kuros Biosciences (SWX: KURN)

›

Kuros Biosciences (SWX: KURN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 213 employees.

The shares were at 18.78 CHF on 20 November 2026, down 31.2% over 52 weeks. Its 52-week range is 16.46 CHF to 32.48 CHF: the price is 42.2% below the high and 14.1% above the low.

At a market capitalisation of 746.63M CHF, it trades at 110.5 times trailing earnings and 34.0 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a premium of 333% for KURN.

Kuros Biosciences reports return on equity of 3.0%, an operating margin of 6.1% and revenue up 45.5% year over year.

Its debt exceeds its cash by 334.00K USD, a debt-to-equity ratio of 0.02. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 3 analysts cover the stock; their mean price target of 34.33 CHF is 82.8% above the current price. The next earnings report is expected on 3 March 2027.